Hyperoxia and Microvascular Dysfunction
Primary Purpose
Coronary Microvascular Disease, Microvascular Disease, Ischemic Heart Disease
Status
Terminated
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Hyperoxia
Normoxia
laser Doppler
Sponsored by
About this trial
This is an interventional basic science trial for Coronary Microvascular Disease focused on measuring cardiac microvascular dysfunction, subcutaneous microvascular dysfunction, ischemic heart disease, oxydative stress
Eligibility Criteria
Inclusion Criteria:
- Coronary angiography done in the context of suspicion of coronary artery disease (CAD)
Exclusion Criteria:
- Respiratory failure requiring intubation or supplementary oxygen
- Severe chronic obstructive pulmonary disease
- Significant arrhythmia precluding waveform analysis (e.g., excessive premature ventricular contractions or atrial fibrillation)
- Severe valvular heart disease,
- Suspected elevated central venous pressure (CVP)
- Heart failure as defined by New York Heart Association class III or IV
- Previous coronary revascularization or heart transplantation
- Severe hypertension (systolic pressure >200 mmHg and diastolic pressure >120 mmHg at rest)
- Contraindications to adenosine infusion
- Contraindication to acetylcholine (Ach) infusion
- Severe bronchial asthma.
Sites / Locations
- Erasme Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Hyperoxia
Normoxia
Arm Description
assessment of forearm skin microcirculatory blood flow by laser Doppler perfusion imager at baseline and during hyperemic tests assessment of coronary microcirculatory blood flow at baseline and during hyperemic tests
assessment of forearm skin microcirculatory blood flow by laser Doppler perfusion imager at baseline and during hyperemic tests assessment of coronary microcirculatory blood flow at baseline and during hyperemic tests
Outcomes
Primary Outcome Measures
Change from baseline in the acetylcholine-induced skin blood flow after hyperoxia
Measurement of skin blood flow before, during and after hyperoxia, expressed in perfusion units (arbitrary units).
Change from baseline in the sodium nitroprusside-induced skin blood flow after hyperoxia
Measurement of skin blood flow before, during and after hyperoxia, expressed in perfusion units (arbitrary units).
Change from baseline in the heat-induced skin blood flow after hyperoxia
Measurement of skin blood flow before, during and after hyperoxia, expressed in perfusion units (arbitrary units).
Change from Baseline in the index of microcirculatory resistance Under adenosine after hyperoxia
Measurement of coronary microcirculatory resistance (index of microcirculatory resistance) Under adenosine before and after hyperoxia, expressed in arbitrary units
Change from Baseline in the index of microcirculatory resistance at rest after hyperoxia
Measurement of coronary microcirculatory resistance (index of microcirculatory resistance) at rest before and after hyperoxia, expressed in arbitrary units
Secondary Outcome Measures
Full Information
NCT ID
NCT04321434
First Posted
January 16, 2017
Last Updated
March 24, 2020
Sponsor
Université Libre de Bruxelles
1. Study Identification
Unique Protocol Identification Number
NCT04321434
Brief Title
Hyperoxia and Microvascular Dysfunction
Official Title
Cardiac and Subcutaneous Microvascular Dysfunction in Patients With Ischemic Heart Disease: Effects of an Acute Oxidative Stress
Study Type
Interventional
2. Study Status
Record Verification Date
March 2020
Overall Recruitment Status
Terminated
Why Stopped
Futility
Study Start Date
December 1, 2016 (undefined)
Primary Completion Date
April 1, 2018 (Actual)
Study Completion Date
October 1, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Université Libre de Bruxelles
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Coronary artery disease (CAD) pathophysiology involves endothelium-dependent (e.g. nitric oxide, acetylcholine) and -independent (e.g. adenosine) vascular dilation impairment, which have been demonstrated at the level of small coronary arteries, medium sized peripheral arteries and subcutaneous microcirculation. Oxygen supplementation, which is frequently overused in clinical settings, seems harmful in acute coronary syndromes and increases microvascular resistance in myocardial and subcutaneous microcirculation through alteration of endothelium-dependent and -independent dilation by an oxidative mechanism. Whether endothelial dysfunction, that is well documented at the level of cardiac microcirculation in CAD patients, is also present at the level of subcutaneous microcirculation is unknown. Also, unknown is whether an acute oxidative stress can be used to probe myocardial microcirculatory dysfunction at the level of subcutaneous microcirculation, which is an easily accessible vascular bed for an in vivo assessment of endothelial-dependent and-independent function. Alterations in cutaneous vascular signalling are evident early in the disease processes. Thus, studying subcutaneous circulation in patients with cardiovascular risk factors could provide vascular information early in CAD processes. This study will test the following 4 hypotheses:
Endothelial dysfunction observed at the level of microvascular cardiac arteries is readily present at the level of subcutaneous microcirculation in a given CAD patient.
An acute oxidative stress such as hyperoxia can be used to test myocardial microcirculatory dysfunction at the level of the more easily accessible subcutaneous microcirculation.
Subcutaneous microcirculation of CAD patients has a lesser vasodilatory response to acetylcholine or sodium nipride than matched healthy subjects. In addition, CAD patients are more prone to dermal vasoconstriction in response to oxygen compared to healthy subjects.
Taken that oxygen is still too often given in excess in most clinical settings, the aim of this study is to rule out possible pitfalls in coronary pressure and resistance determinations in CAD patients receiving unnecessary oxygen supplementation.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Microvascular Disease, Microvascular Disease, Ischemic Heart Disease
Keywords
cardiac microvascular dysfunction, subcutaneous microvascular dysfunction, ischemic heart disease, oxydative stress
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Hyperoxia
Arm Type
Experimental
Arm Description
assessment of forearm skin microcirculatory blood flow by laser Doppler perfusion imager at baseline and during hyperemic tests
assessment of coronary microcirculatory blood flow at baseline and during hyperemic tests
Arm Title
Normoxia
Arm Type
Placebo Comparator
Arm Description
assessment of forearm skin microcirculatory blood flow by laser Doppler perfusion imager at baseline and during hyperemic tests
assessment of coronary microcirculatory blood flow at baseline and during hyperemic tests
Intervention Type
Other
Intervention Name(s)
Hyperoxia
Intervention Type
Other
Intervention Name(s)
Normoxia
Intervention Type
Device
Intervention Name(s)
laser Doppler
Intervention Description
laser Doppler
Primary Outcome Measure Information:
Title
Change from baseline in the acetylcholine-induced skin blood flow after hyperoxia
Description
Measurement of skin blood flow before, during and after hyperoxia, expressed in perfusion units (arbitrary units).
Time Frame
1 hour
Title
Change from baseline in the sodium nitroprusside-induced skin blood flow after hyperoxia
Description
Measurement of skin blood flow before, during and after hyperoxia, expressed in perfusion units (arbitrary units).
Time Frame
1 hour
Title
Change from baseline in the heat-induced skin blood flow after hyperoxia
Description
Measurement of skin blood flow before, during and after hyperoxia, expressed in perfusion units (arbitrary units).
Time Frame
1 hour
Title
Change from Baseline in the index of microcirculatory resistance Under adenosine after hyperoxia
Description
Measurement of coronary microcirculatory resistance (index of microcirculatory resistance) Under adenosine before and after hyperoxia, expressed in arbitrary units
Time Frame
10 minutes
Title
Change from Baseline in the index of microcirculatory resistance at rest after hyperoxia
Description
Measurement of coronary microcirculatory resistance (index of microcirculatory resistance) at rest before and after hyperoxia, expressed in arbitrary units
Time Frame
10 minutes
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Coronary angiography done in the context of suspicion of coronary artery disease (CAD)
Exclusion Criteria:
Respiratory failure requiring intubation or supplementary oxygen
Severe chronic obstructive pulmonary disease
Significant arrhythmia precluding waveform analysis (e.g., excessive premature ventricular contractions or atrial fibrillation)
Severe valvular heart disease,
Suspected elevated central venous pressure (CVP)
Heart failure as defined by New York Heart Association class III or IV
Previous coronary revascularization or heart transplantation
Severe hypertension (systolic pressure >200 mmHg and diastolic pressure >120 mmHg at rest)
Contraindications to adenosine infusion
Contraindication to acetylcholine (Ach) infusion
Severe bronchial asthma.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean-Paul Van Vooren, MD, PhD
Organizational Affiliation
Hospital Erasme
Official's Role
Study Director
Facility Information:
Facility Name
Erasme Hospital
City
Brussels
State/Province
Brabant
ZIP/Postal Code
1070
Country
Belgium
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Hyperoxia and Microvascular Dysfunction
We'll reach out to this number within 24 hrs